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論 文 内 容 の 要 旨  
 
Introduction 
Enhancer of zeste homolog 2 (EZH2) and its homolog EZH1, the catalytic components of polycomb 
repressive complex 2 (PRC2), are methyltransferases that induce the trimethylation of histone H3 at 
lysine 27 generating H3K27me3, leading to repression of the transcription of target genes. PRC2 
components have been implicated in the pathogenesis of different kinds of cancer. Specifically, 
EZH2 is highly expressed in solid malignancies such as breast, prostate and bladder cancers as well 
as in multiple myeloma (MM). Overexpression of EZH2 correlated with disease progression and 
aggressiveness. Recently, several dual EZH2/1 inhibitors have been developed with promising 
preliminary reports in non-Hodgkin lymphomas (NHLs). 
In this study, we investigated the pre-clinical therapeutic efficacy of the combination of UNC1999, a 
novel EZH2/1 inhibitor, and proteasome inhibitors in PRC2-dependent tumors: multiple myeloma 
and prostate cancer. 
Results 
We demonstrated that PRC2 was a valid target for the treatment of MM as evidenced by the growth 
inhibitory effects of EZH2 knockdown and dual inhibition of EZH2/1 by UNC1999 on MM cells. 
Remarkably, MM cells acquired resistance to proteasome inhibition following EZH2 overexpression 
using lentiviral vectors. Interestingly, this resistance was overcome by UNC1999. Importantly, we 
found that proteasome inhibitors downregulated EZH2 transcription via disruption of Rb-E2F 
pathway, however, EZH1 was not affected and H3K27me3 mark remained largely unchanged. In 
vitro as well as in vivo synergistic anti-myeloma effects of the combination of UNC1999 and 
proteasome inhibitors were illustrated. Remarkably, combining proteasome inhibitors with 
UNC1999 resulted in a more synergistic effect than with a specific EZH2 inhibitor.   This 
suggested that inhibition of both EZH2 and EZH1 was needed to completely block PRC2 activity in 
MM cells. Comprehensive genomic analysis uncovered the direct targets of UNC1999 in MM which 
included the tumor suppressor NR4A1. Activation of NR4A1 was associated with repression of MYC, 
which was further enhanced by the combination of UNC1999 and proteasome inhibitors. Potent 
synergistic effect of the combination of UNC1999 and proteasome inhibitors was also observed in 
prostate cancer cell lines. 
Conclusion 
Our study provides pre-clinical evidence of the promising therapeutic value of the combination of 
PRC2 inhibition and proteasome inhibition in the treatment of PRC2-dependent cancers. 
 
 
 
 
 
論 文 審 査 の 結 果 の 要 旨 
 
In this study, the candidate investigated the utility of dual inhibition of EZH2 and EZH1 alone and 
in combination with proteasome inhibitors in multiple myeloma. She illustrated PRC2-dependency in 
multiple myeloma cells using EZH2/1 knockdown and pharmacological inhibition of EZH2 and 
EZH1. She showed that the proteasome inhibitor, bortezomib, markedly downregulated EZH2 via 
abrogation of RB-E2F pathway, while maintaining H3K27me3 mark with intact EZH1. She proved 
the synergistic activity between dual inhibition of EZH2 and EZH1 and proteasome inhibition in vitro 
and in vivo, suggesting that the dual inhibition of EZH2 and EZH1 sensitized myeloma cells to 
proteasome inhibition. Genome wide analysis revealed that the combination therapy enhanced 
de-repression of PRC2 target genes including NR4A1 and the subsequent MYC suppression. This 
combination also exhibited strong synergy in prostate cancer cells, indicating that the dual inhibition 
of PRC2 together with proteasome inhibition represented a novel therapeutic strategy for 
PRC2-dependent tumors. 
We hereby certify that the above-mentioned thesis is academically satisfactory in scope and 
quality. 
 
 
 
